Tasigna

Popular Leukemia Drug Linked to Deadly Atherosclerosis

Tasigna LawsuitsTasigna (nilotinib) is a powerful drug used to treat chronic myeloid leukemia. Tasigna works by blocking certain proteins, thereby preventing cancer cell growth in patients. New lawsuits point to a connection between Tasigna and the deadly condition of atherosclerosis, which causes plaque to build up in arteries.

Who Uses Tasigna?

Tasigna, also know in it’s generic form as nilotinib, is used to treat patients suffering from Philadelphia chromosome-positive chronic myelogenous leukemia (CML), a condition that affects the body’s white blood cells. Tasigna was approved for use by the FDA in 2007, and was developed and sold by the pharmaceutical company Novartis.

Tasigna is in a class of drugs known as tyrosine kinase inhibitors (TKIs). These drugs block the certain proteins in the body  called tyrosine kinases, thereby limiting the progression of leukemia.

Tasigna Lawsuits

Patients in the United States are currently filing lawsuits against Tasigna manufacturer Novartis due to the risk of developing atherosclerosis while taking the drug. In 2013, Novartis issued health warnings to consumers and physicians in Canada and other countries warning them about the increased risk of developing atherosclerosis. No such warnings were provided to patients and physicians in the United States, despite a global review of Tasigna revealed 277 reports cases of atherosclerosis dating back to 2005.

If you or a family member have taken Tasigna and developed atherosclerosis or other vascular diseases, you may be entitled to compensation from the manufacturer for your injuries. The Tasigna lawsuit attorneys at Aylstock, Witkin, Kreis & Overholtz are happy to provide a free consultation. Contact us today by calling toll free at (844) 794-7402 or use the form below. There are no fees or costs unless we recover compensation for you.

Bibliography and References

Bibliography
If additional resources are available, they will be linked here.
Additional Resources
If additional resources are available, they will be linked here.